
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics is well-positioned for future success and revenue growth with their investigational therapy Haduvio, as seen through their recent positive clinical trial results and planned Phase 3 trials for IPF-related chronic cough and RCC. The company has also taken measures to strengthen their financial position, including hosting an Analyst Day and successfully completing a $150 million stock offering. While there are still risks involved in the clinical development and potential commercialization of Haduvio, Trevi Therapeutics shows promising potential as a leader in the treatment of chronic cough.
Bears say
Trevi Therapeutics is taking a multi-indication approach with the investigational therapy Haduvio, but a lack of approved therapies in chronic cough populations and potential financial risks from partnerships and acquisitions may limit its success. With upcoming catalysts in the form of trials and an investor day, the stock could see some short-term gains, but a negative outlook remains due to the lack of approved therapies and potential risks.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares